DexCom stock

DXCM · NASDAQ · USD

Compare DexCom
$83.33Change from previous close: +2.38%Absolute change: +$1.94

Close · November 13, 2026

Price history

+39.53% over the period

1 year: from $59.72 (November 13, 2025) to $83.33 (November 13, 2026), +39.53%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$83.33
October 30, 2026$82.29
September 30, 2026$86.29
August 31, 2026$91.06
July 31, 2026$83.45
June 30, 2026$67.35
May 29, 2026$73.74
April 30, 2026$59.55
March 31, 2026$62.80
February 27, 2026$73.43
January 30, 2026$73.04
December 31, 2025$66.37
November 28, 2025$63.47
November 13, 2025$59.72

At a glance

  • The company

    Designs and commercializes continuous glucose monitoring systems for diabetes and metabolic health management

  • Latest results

    Quarter to September 30, 2026 · EPS $0.73 (estimate $0.67)

TickerLandia's take on DexCom

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$56.72
52-wk high$92.59

−10.00% from the 52-week high

Analysts · 29 analysts

Average target$98.58+18.30% vs. price

Buy 26 · Hold 3 · Sell 0 · Strong buy

TickerLandia Fingerprint: DexCom

Compared with similar companies: very high profitability.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

DexCom is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), DexCom's P/E today is 39.9, below the median of its last 6 fiscal years (82.5; between 31.8 and 253.3 from 2020 to 2025). DexCom's P/E (trailing 12 months): 32.8, +14% against the median of a group of 10 similar companies (28.7).

P/E compared with its history

Compared with 10 similar companies

DexCom's metrics compared with similar companies
MetricDexComPosition in the groupBand
P/E (trailing 12 months)32.8Middle
Forward P/E26.6High
Operating margin24.0%High
ROE37.7%High
Debt/equity0.55Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: DexCom. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.31B

Latest quarter · Q2 2026

Net income

$249.1M

Latest quarter · Q2 2026

Quarterly net margin

19.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$31.08B
P/E
32.8
EPS
$2.54
Volume
3.01M
Daily trading
€366.95M
Dividend yield
0.00%

How DexCom is changing

All results
  • Revenue grew 19.3% a year on average over the last 5 years

  • Operating margin rose from 13.4% to 19.6%

  • Profits turn into cash: free cash flow equal to 114% of net income

Returns

DexCom returns

$1,000 invested in DexCom 5 years ago, on November 15, 2021, would be worth $519 today: −48.08% in total, −12.30% per year. This is the price return only: dividends are excluded.

PeriodDexComS&P 500$1,000 becomes
1 month−2.03%−3.12%$980
6 months+42.27%+1.58%$1,423
Year to date+25.55%+10.46%$1,256
1 year+39.53%+12.23%$1,395
3 years−15.27%+71.41%$847
5 years−48.08%+61.48%$519
10 years+384.55%+249.40%$4,845

Over the last 6 months it has done better than 81% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

DexCom: technical analysis

DexCom shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 48.8% below its all-time closing high ($162.82, November 17, 2021).

Trend
No clear trend
RSI (14 sessions)
51
Between 30 and 70
vs 200-session average
+10.99%

Support and resistance

Price areas where DexCom has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$92.46+10.96%2 touches, last on September 1, 2026
  2. Resistance$90.32+8.39%2 touches, last on November 5, 2026
  3. Resistance$88.19+5.83%2 touches, last on October 16, 2026
  4. Last price$83.33
  5. Support$82.58−0.91%2 touches, last on October 6, 2026
  6. Support$79.03−5.16%2 touches, last on July 16, 2026
  7. Support$75.59−9.29%4 touches, last on October 26, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.73
Volatility (60 sessions, annualised)
36.2%
Largest fall in the last year
−22.61%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

DexCom: seasonality

Average monthly price change over 22 years

+6.8%Jan+0.6%Feb+0.9%Mar+5.4%Apr+3.9%May+5.2%Jun−0.4%Jul+8.4%Aug−4.3%Sep−3.2%Oct+3.3%Nov+4.5%Dec

Over the last 22 years, the strongest month for DexCom has been August: +8.40% on average, positive in 17 years out of 22. The weakest has been September: −4.26% on average, positive in 6 years out of 22. November, the current month, has been positive in 12 years out of 21 (+3.27% on average).

Show chart data
MonthAverageMedianPositive years
January+6.80%+10.05%15 of 21
February+0.55%−1.21%9 of 21
March+0.88%+2.63%12 of 21
April+5.37%+1.65%12 of 21
May+3.91%+1.33%13 of 22
June+5.22%+8.69%16 of 22
July−0.41%−2.05%10 of 22
August+8.40%+9.26%17 of 22
September−4.26%−3.54%6 of 22
October−3.23%−5.90%8 of 22
November+3.27%+2.04%12 of 21
December+4.53%+3.90%12 of 21

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

DexCom and its competitors

Its core activity is the design, development and sale of continuous glucose monitoring devices for people with diabetes and for metabolic health management. The range includes the Dexcom G7 and G7 15 Day integrated sensor, the Dexcom G6 system, and the Dexcom ONE+, which is intended to replace fingerstick testing in treatment decisions. The company also offers Stelo, a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin, together with Dexcom Share for remote monitoring and the Dexcom Follow app.

Headquarters
San Diego, United States
Employees
11,000
Founded
1999
Chief executive
Jacob Leach
DexCom and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
DexComDXCM$31.08B24.0%32.8+42.27%
GE HealthCare TechnologiesGEHC$37.54B13.8%17.6+34.14%
SterisSTE$25.67B19.2%31.4+25.21%
Zimmer Biomet HoldingsZBH$19.53B16.7%26.1+24.77%
Edwards LifesciencesEW$61.61B28.8%61.6+31.65%
Boston ScientificBSX$64.27B19.6%18.7−16.43%

Same industry or related industries, similar size. Compare DexCom with its competitors · Full profile